Susceptibility-Weighted MR Imaging Hypointense Rim in Progressive Multifocal Leukoencephalopathy: The End Point of Neuroinflammation and a Potential Outcome Predictor

M.M. Thurnher, J. Boban, A. Rieger, and E. Gelpi

ABSTRACT

BACKGROUND AND PURPOSE: Progressive multifocal leukoencephalopathy (PML) represents a life-threatening demyelinating disorder of the brain caused by reactivation of a rare opportunistic infection with JC Polyomavirus. The aims of this study were to describe the incidence of a susceptibility-weighted imaging hypointense rim in patients with multifocal leukoencephalopathy and to explore the histologic correlates and prognostic value of the rim with regard to the clinical outcome.

MATERIALS AND METHODS: This retrospective study included 18 patients with a definite diagnosis of progressive multifocal leukoencephalopathy. Ten patients were HIV-positive, 3 patients had natalizumab-associated progressive multifocal leukoencephalopathy, 1 patient had multiple myeloma, 3 patients had a history of lymphoma, and 1 was diagnosed with acute myeloid leukemia. Patients were divided into short- (up to 12 months) and long-term (>12 months) survivors. A total of 93 initial and follow-up MR imaging examinations were reviewed. On SWI, the presence and development of a hypointense rim at the periphery of the progressive multifocal leukoencephalopathy lesions were noted. A postmortem histologic examination was performed in 2 patients: A rim formed in one, and in one, there was no rim.

RESULTS: A total of 73 progressive multifocal leukoencephalopathy lesions were observed. In 13 (72.2%) patients, a well-defined thin, linear, hypointense rim at the periphery of the lesion toward the cortical side was present, while in 5 (27.8%) patients, it was completely absent. All 11 long-term survivors and 2 short-term survivors presented with a prominent SWI-hypointense rim, while 5/7 short-term survivors did not have this rim.

CONCLUSIONS: The thin, uniformly linear, gyriform SWI-hypointense rim in the paralesional U-fibers in patients with definite progressive multifocal leukoencephalopathy might represent an end-point stage of the neuroinflammatory process in long-term survivors.

ABBREVIATIONS: JCV = JC Polyomavirus; PML = progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML) is an infectious demyelinating disease of the central nervous system, caused by reactivation and replication of the JC Polyomavirus (JCV). Although PML was traditionally associated with HIV/AIDS, a shift toward patients on immunomodulation therapy has been observed in the past decade. Furthermore, PML has also been reported in patients with immune deficits associated with hematologic disorders. The MR imaging features of PML include single or multiple T2-weighted and FLAIR-hyperintense white matter lesions. Lesion borders are usually sharply demarcated toward the gray matter and blurred toward the deep white matter or ventricles, with absent or only faint contrast enhancement. On diffusion-weighted imaging, a high-signal-intensity rim of restricted diffusion that represents active demyelination has been described. To date, no specific features on conventional MR images have been identified as predictive of patient survival. Recently, the presence of a dark rim adjacent to the cortex or in the deep cortical layers on susceptibility-weighted imaging was reported in 2 patients with PML. Data based on quantitative susceptibility mapping of the lesions suggested a paramagnetic (blood product or nonheme iron deposits) effect. However, the mechanism that led to the susceptibility change remains unclear, because no histologic correlation was performed. SWI is a recently introduced MR imaging technique that has been used to...
evaluate hemorrhage, quantify brain iron content, and identify brain calcifications.\textsuperscript{12}

The aims of this retrospective study were to describe the incidence of an SWI-hypointense rim in patients with PML, to elucidate the histologic correlate of this rim, and to explore the prognostic value of the observed SWI features with regard to the clinical outcome.

**MATERIALS AND METHODS**

**Study Population**

A total of 18 consecutive patients with a definite diagnosis of PML (13 male and 5 female patients), with an average age of 50.56 years (range, 26–75 years) who underwent MR imaging of the brain at our institution from September 2009 to December 2018 were included in this institutional review board (Ethics Committee of the Medical University Vienna)–approved, retrospective study. Patients with no SWI in any of the MR imaging examinations were excluded. Ten (55.6%) patients were HIV-positive, 3 (16.7%) had natalizumab-associated PML, 1 patient (5.6%) had multiple myeloma, 3 patients (16.7%) had lymphoma, and 1 patient (5.6%) had acute myeloid leukemia and bone marrow transplantation. Of the 3 patients with lymphoma, 1 patient had large-cell lymphoma, 1 patient had small-cell B-cell lymphoma in remission, 1 patient was being treated with rituximab, and 1 patient had non-Hodgkin lymphoma. In 1 patient, herpes simplex virus type 2 encephalitis was also diagnosed, and 5 patients had a chronic coinfection with the hepatitis C virus. The diagnosis of definite PML in all patients was established on the basis of clinical data, imaging findings, and detection of DNA copies of the JCV in all patients (patients 2 and 16 in the On-line Table). Formalin-fixed and paraffin-embedded tissue blocks from multiple brain areas, including a whole, representative hemispheric section, were processed for conventional histologic and immunohistochemical stains. Five-μm-thick sections were stained with hematoxylin-eosin, as well as Klüver-Barrera (Luxol fast blue and Nuclear fast red) for the labeling of myelin sheaths, and, in selected areas, with Prussian blue for the detection of iron. Immunohistochemistry was applied for the detection of the JCV and for the evaluation of astroglia (glial fibrillary acidic protein, GFAP; Dako, Glostrup, Denmark) and microglia (HLA-DR; Dako).

**MR Imaging Protocol**

Ninety-one MR imaging examinations were performed in 18 patients on different clinical MR imaging scanners (Avanto, Siemens, Erlangen, Germany, 1.5T; Tim Trio, Siemens, 3T; Ingenia, Philips Healthcare, Best, the Netherlands, 1.5T; Achieva, Philips Healthcare, 3T). The MR imaging protocol included the following sequences: axial FLAIR, coronal T2-weighted, axial T1-weighted, and axial diffusion-weighted MR imaging in all patients. Postcontrast T1WI was performed in all patients (82/91 examinations). SWI was performed in all patients (74/91 examinations). Susceptibility-weighted imaging was performed with the following parameters: FOV = 230 × 190 × 130 mm (anterior-posterior × right-left × height-feet), voxel size = 0.6 × 0.6 × 1 mm, reconstruction matrix = 960, TE/TR = 7.12/31 ms, flip angle = 17° with no water or fat suppression used (3T MR imaging unit, Tim Trio). Parameters for the SWI sequence on the 1.5T MR imaging unit (Avanto) were the following: FOV = 230 × 186 × 150 mm, voxel size = 0.85 × 1 × 2 mm, reconstruction matrix = 576, TE/TR = 12/35 ms, flip angle = 20° with no water or fat suppression.

**Image Analysis**

Overall, 91 MR imaging examinations were analyzed, with a mean of 4.17 follow-up imaging studies per patient (range, 0–11 studies).

All imaging studies were analyzed independently on a digital workstation by 2 readers and in a final consensus read (M.M.T., J.B.). The morphologic findings of lesions were described, including the lesion location, the size and number, and lesion features on pre- (T2WI, FLAIR, T1WI, DWI) and postcontrast T1WI. On SWI, the presence or absence of a hypointense rim at the periphery of the PML lesions was noted. The development of this rim with time was estimated, compared with prior images, and expressed in weeks. In addition, the correlation of the onset of an SWI-hypointense rim, DWI abnormalities, and the presence of contrast enhancement was explored.

**Neuropathology**

A postmortem neuropathologic examination was performed in 2 patients (patients 2 and 16 in the On-line Table). Formalin-fixed and paraffin-embedded tissue blocks from multiple brain areas, including a whole, representative hemispheric section, were processed for conventional histologic and immunohistochemical stains. Five-μm-thick sections were stained with hematoxylin-eosin, as well as Klüver-Barrera (Luxol fast blue and Nuclear fast red) for the labeling of myelin sheaths, and, in selected areas, with Prussian blue for the detection of iron. Immunohistochemistry was applied for the detection of the JCV and for the evaluation of astroglia (glial fibrillary acidic protein, GFAP; Dako, Glostrup, Denmark) and microglia (HLA-DR; Dako).

**Statistical Analysis**

Descriptive statistics were used for various findings on MR imaging. For categoric data, we used frequencies and percentages, while for continuous data, range and median values were used. Survival was estimated using Kaplan-Meier estimates. The results are presented in a pictorial-review format.

**RESULTS**

**Clinical Data**

All patients fulfilled the American Academy of Neurology criteria for definite PML. Among HIV-positive subjects, the median duration of HIV infection before the onset of PML was 5.88 years (range, 0–23 years). The median nadir CD4 count, plasma viral load, duration of the HIV infection; neurologic signs and symptoms at the PML onset; and duration of antiretroviral therapy. In 2 HIV-negative patients, the neurologic signs and symptoms and the time range between the onset of PML and the underlying disease were noted. For natalizumab-associated PML, we included the following clinical data: current and nadir CD4 count, plasma viral load, duration of natalizumab therapy.

Patients were classified as long- or short-term survivors, with a survival time of up to 12 months for short-term survivors and longer than 12 months for long-term survivors. The aims of this retrospective study were to describe the incidence of an SWI-hypointense rim in patients with PML, to elucidate the histologic correlate of this rim, and to explore the prognostic value of the observed SWI features with regard to the clinical outcome.
detection level) after cART initiation. In 4 (40%) patients, PML was the initial manifestation of the HIV infection/AIDS. Neurologic symptoms at presentation are listed in the On-line Table.

Three patients (18.75%) were receiving HAART before the PML diagnosis (median duration of cART was 5.33 years; range, 3–9 years). In all patients, DNA copies of the JCV were detected in the CSF. One patient presented with B-cell chronic lymphocytic leukemia. In 1 patient with acute myeloid leukemia and bone marrow transplantation, the diagnosis of PML was made 3 months after the bone marrow transplantation. One patient was under immunomodulatory therapy for multiple myeloma. Of the 3 patients with natalizumab PML, all had relapsing-remitting MS diagnosed 5–12 years (mean, 8.3 years) before the onset of PML. The duration of natalizumab therapy was 3.6 years (4 years, 3 years, 3 years, respectively).

Seven patients were classified as short-term survivors, with a mean survival time of 2.93 months (range, 1–6 months). The cause of death was PML in 3 patients, and 1 patient died due to a non-PML cause (lung embolism). One short-term survivor (with a defined SWI-hypointense rim) has survived 5 months and is alive and stable at the moment. In 11 patients classified as long-term survivors, the mean survival time was 81.82 months (range, 20–198 months).

The results of the survival analysis clearly demonstrate differences in survival and outcome between patients with (in purple) and without (in orange) an SWI-hypointense rim.

MR Imaging Findings
A total of 73 PML lesions were observed in 18 patients, involving the frontal (31/42.4%), parietal (9/12.3%), temporal (5/6.8%), and occipital (6/8.2%) lobes, and the insular region (4/5.5%), the external capsule (1/1.4%), the internal capsule (2/2.8%), the thalamus (1/1.4%), the corpus callosum (1/1.4%), the pons (1/1.4%), and the cerebellum (9/12.3%). All lesions had typical MR imaging features—that is, high signal on T2WI/FLAIR and marked low signal on T1WI. Only 2 of 18 patients (11.1%) showed a peripheral rim of restricted diffusion on DWI with corresponding low ADC values.

Contrast enhancement was present in 10/18 (55.6%) patients. According to the enhancement pattern, patients were divided into 4 groups: 1) “No enhancement” was seen in 8/18 (44.4%) patients (2 patients with lymphoma, 2 with MS, 1 patient with multiple myeloma, and 3 HIV-positive patients); 2) “faint enhancement” was detected in 5/18 (27.8%) patients (3 HIV-positive patients, 1 patient with MS, and 1 patient with lymphoma); 3) an “inflammatory pattern” was seen in 2/18 (11.2%) patients (1 HIV-positive patient, 1 patient with acute myeloid leukemia and bone marrow transplantation); and 4) an “immune reconstitution inflammatory syndrome pattern” was present in 1 of 18 (5.6%) patients (an HIV-positive patient).

SWI Findings
SWI findings were available for all 18 patients. On SWI, a well-defined thin, linear, hypointense rim at the periphery of the lesion, located toward the cortical side (Fig 2), was present in 13/18 patients (72.2%); while in 5 patients (27.8%), the rim was completely absent (Fig 3). Of 16 patients in whom SWI was performed within the first 2 months after the PML diagnosis, the presence of an SWI-hypointense rim was detected in 11 patients, with the mean time to formation of 2.8 weeks (range, 1–8 weeks). In 1 patient, the first signs of an SWI-hypointense rim were observed 13 weeks after the initial MR imaging examination, but the follow-up examination was not performed within the first 2 months. In addition, in 1 patient, the first SWI data were available 6 years after the diagnosis, with a positive SWI-hypointense rim (burn-out lesion). The SWI-hypointense rim gradually increased in thickness with time, spreading continuously along the juxtacortical white matter following the gyral architecture.

Correlation of SWI and Contrast Enhancement and DWI Findings
At the time of the first appearance of the SWI dark rim, only 4 patients had contrast enhancement. However, this contrast enhancement was not located at the SWI-hypointense rim, but either on the peripheral rim of the PML lesion toward the ventricle or closer to the center of the PML lesion (faint or dotty enhancement). Contrast enhancement was not observed in the region of FIG 1. Kaplan-Meier survival analysis, with differences in survival and outcome between patients with (in purple) and without (in orange) an SWI-hypointense rim.
the SWI-hypointense rim in any of the examinations in which postcontrast T1WI was available for analysis.

In 2 patients (patients 8 and 12) in whom a DWI-hyperintense rim was present, SWI did not show a dark rim. In 1 patient (patient 12) in whom follow-up was available, 3 weeks after the initial examination, the DWI rim disappeared and the SWI rim was detected (Fig 4).

**Neuropathologic Findings**
A neuropathologic examination was performed in 2 patients, (patients 2 and 16 in the On-line Table); in 1 patient, an SWI rim was present (patient 2), but no SWI rim was detected in the second patient (patient 16). Patient 2, with a survival time of 6 months, died of multiorgan dysfunction syndrome, and in patient 16, the cause of death was PML.

In patient 2 (On-line Figure A1), gross examination showed multiple white matter lesions in both hemispheres, some of which were softened and yellowish and were most pronounced at the frontal regions with an already necrotic aspect. Histology showed features of an extensive inflammatory demyelinating pathology with prominent loosening of white matter, loss of myelin sheaths with relatively preserved axons, abundant macrophages, and perivascular lymphocytic infiltrates. No parenchymal bleeding was observed.

In patient 16 (On-line Figure B1), gross examination showed multiple and partly confluent and softened white matter lesions mainly in the left-brain hemisphere, extending from the frontal to the parietotemporal regions, with relative preservation of the overlying cortex. Histology confirmed the inflammatory and demyelinating nature of the lesion (On-line Figure B5). No parenchymal bleeding was detected.

In patient 2 with the faint SWI rim, the number of PML-infected cells was much lower than in the patient without an SWI rim (On-line Figure A5 and B5). In addition, there was much more prominent astrogliosis and microglial activation in the deep cortical layers and at the cortical-subcortical junction, including the U-fibers (On-line Figure A6 and A7). This feature was observed not only in areas overlying PML lesions but also in areas without focal lesions, but with diffuse white matter pallor and moderate gliosis. In both cases, a Prussian blue stain was performed for the detection of iron deposits. In patient 2,
abundant blue pigment was observed within actively demyelinat-
ing lesions (On-line Figure A3, triple asterisks). In the surround-
ing areas, diffuse homogeneous cytoplasmic staining of pericap-
illary cells was also observed (On-line Figure A3, double asterisks). In contrast, around vessels with moderate chronic gli-
osis, there was glial pigment and non-Prussian blue pigment al-
ternating with Prussian blue pigment (On-line Figure A3, as-
terisk). In patient 16, fewer perivascular Prussian blue–
positive areas were detected.

**DISCUSSION**

PML represents a life-threatening demyelinating disease of the
brain as a result of infection with the JCV. Since the AIDS epi-
demic, PML was reported exclusively in association with HIV, but
more recently, there has been a shift toward other immunosup-
pressive conditions, including patients on immune-suppression
therapy and patients with long-standing autoimmune inflamma-
tory or hematologic malignancies. In addition, several case
reports on immunocompetent patients developing PML have also
been published.

A relatively thin, uniformly linear SWI-hypointense rim was
observed in 13 of 18 patients with PML in our study. The rim
exclusively affected the U-fibers, following the cortical architec-
ture, and did not correlate with other MR imaging findings. No
signs of susceptibility changes were detected in the center of the
PML lesions or on the side toward the deep white matter and the
ventricle. In addition, infratentorial PML lesions showed no SWI-
hypointense rim formation. Eleven of 13 patients in whom the
SWI-hypointense rim was present were long-term survivors, whereas in 5 of 7 short-term survivors, there was no SWI-hypointense rim detected. One of our short-term survivors died due to a non-PML cause, and the SWI-hypointense rim in this particular patient could not be seen in correlation with the short survival (patient 2 in the On-line Table). One short-term survivor is still alive (patient 17 in the On-line Table), and because the cutoff point of 12 months has not yet been reached, this patient was
classified as a short-term survivor, though a positive clinical out-
come is highly likely at the moment.

The detection of the linear hypointense rim in the region of the
U-fibers on SWI sequences has only recently been described and
was postulated to be a specific finding in PML lesions. Later, the
same group reported the presence of such a rim in patients with
chronic cerebral infarction and after encephalitis. The etiology
of this rim was unresolved and was not fully explained. Carra-
Dalliere et al suggested that an SWI-hypointense rim in patients
with PML could be a consequence of paramagnetic material de-
posits, based on quantitative susceptibility mapping. In both
studies, no histologic correlation of SWI findings was available.

Several morphologic phenomena occur at the edges of a PML
lesion and beneath juxtacortical areas, mainly primary oligoden-
droglial dysfunction by JCV infection and consequent myelin de-
genation, microglial activation, astroglial proliferation, and
axonal impairment. Axonal damage can produce retrograde neu-
ronal degeneration and lead to progressive cortical atrophy. It is
known that PML also involves the U-fibers. Chronically activated
glial cells and microglia/macrophages may contain high levels of
iron and pigment within their cytoplasm. In addition, blood-

---

**FIG 4.** On an axial FLAIR image (A), bilateral high-signal-intensity lesions are detected. DWI clearly demonstrates a high-signal-intensity rim at the periphery of the lesion in the right frontal lobe on trace DWI (B), with low ADC values (C) indicating restricted diffusion. On SWI (D), no abnormalities are seen. On follow-up MR imaging (3 months later), atrophic changes with dilation of the ventricles are observed in both hemispheres (more prominent in the right) (E). On DWI/ADC (F and G), no hyperintense rim is present. On SWI (H), a dark rim is clearly visible.
brain barrier disruption caused by PML may lead to leakage of 
heme products into the perivascular space. Although diffuse 
homogeneous cytoplasmic staining of cells reflects the presence of 
ferritin, hemosiderin shows the typical granular particles in lysosomes. We found severe reactive changes at the corticocortical 
boundary surrounding the PML lesions, which were more promi-
inent in the patient with a longer survival. We also observed a 
higher, but not exclusive, ferritin and hemosiderin content within 
the lesions in the patient with a longer survival than in the patient 
with a shorter survival, which was more abundant around small 
vessels and capillaries in the deep cortical layers and at the juxta-
cortical border.

A similar but less prominent SWI-hypointense rim was ob-
served in the deep cortical layers of the precentral gyrus in patients 
with amyotrophic lateral sclerosis. On histopathologic studies, 
intracellular deposits of iron (in the form of ferritin) were con-
ﬁrmed in reactive microglial cells, located in the middle and deep 
layers of the motor cortex, in areas that were affected by neuronal 
loss and axonal degeneration. Kim et al recently reported fer-
ritin accumulation in proliferated microglial cells in severely de-
myelinated U-fibers in patients with adult-onset leukoencepha-
lopathy, with axonal spheroids and pigmented glia, as well as 
treelike SWI hypointensities in the subcortical white matter. In 
recently published studies by van Duijn et al and Bulk et al, a 
bandlike T2*-hypointense cortical rim was observed on 7T in a 
subset of patients with Alzheimer disease, which was believed to 
be derived from increased myelin-associated, nonheme iron in 
the middle layers of the cortex and Baillarger lines and was also 
found in disintegrated axons and microglial cells.

One possible explanation for the specific location of iron de-
position in our patients with PML and in the above-mentioned 
disorders is the fact that subcortical U-fibers have a greater iron 
content than both cerebral gray and white matter, due to the high 
density of iron-rich oligodendrocytes, and are considered slow 
metabolic fibers with a slow myelin turnover. In addition, the 
region of U-fibers has long medullary arterioles and venules in a 
gyriform distribution.

The other important question to address is the cause of iron 
deposition in PML. In 1981, Konijn et al had already suggested 
that ferritin accumulation could be a nonspeciﬁc, acute-phase 
reactant in response to inﬂammation. It seems that accumulating 
iron in proliferated microglial cells is not a speciﬁc ﬁnding in any 
of the above-mentioned neurodegenerative diseases, but rather a 
pattern in progressive and long-standing neuroinflammation.

The fact that siderin- and ferritin-laden macrophages were seen 
in the perivascular region, especially around the small capillaries 
at the gray-white matter interface, indicates the possibility of in-
ﬂammation-induced blood-brain barrier disturbance, with ex-
travasation of blood cells and subsequent perivascular deposition 
of iron and iron end products. If an SWI dark rim does, indeed, 
represent an effective chronic neuroinflammatory response to a 
brain injury, it should then be present in PML long-term survi-
vors and could be considered a sign of end-stage inﬂammation. 
The absence of an SWI dark rim in our short-term survivors fa-
vors this hypothesis.

In a recently published study, a T1WI-hyperintense cortical 
signal on MR imaging has been reported in 61.2% of patients with 
PML. A hyperintense cortical signal was detected adjacent to 
subcortical PML lesions on precontrast T1-weighted MR images 
and resembled the SWI-hypointense rim seen in our patients. In 
addition, atrophy of the cortical area affected was reported in 
96.7% of cases with hyperintense cortical signal. SWI was avail-
able in 15 of 49 patients in that particular study, and none of them 
had any SWI abnormality. On histology, hyperintense cortical 
signal areas were associated with striking JCV-associated demy-
elination of the cortical and subcortical U-fibers, heavy macro-
phage inﬁltration, and a pronounced reactive gliosis in the deep 
cortical layers. There were neither microhemorrhages nor iron 
deposits in the postmortem histologic sections of our 2 patients 
with PML in whom histologic analysis was obtained.

The characteristic MR imaging ﬁnding suggestive of inﬂam-
mation is the presence of contrast enhancement in a given lesion. 
In general, in HIV-related PML, enhancement is observed in only 
up to 15%. This is different for natalizumab-associated PML, in 
which enhancement will be present in 43% of cases. In a recently 
described form of PML, called “inﬂammatory PML,” prominent 
enhancement along the perivascular spaces was observed. These 
lesions show perivascular cuffing and inﬂammatory plasma cell 
infiltrates. It was suggested that this PML form represents the 
fulminant, active, lytic infection of white matter cells caused di-
rectly by the JCV.

In our study, we could not establish a relationship between the 
presence of contrast enhancement and SWI-hypointense rim for-
mation. In 2 of our short-term survivors, MR imaging ﬁndings 
were consistent with an inﬂammatory PML pattern, and neither 
of them developed an SWI-hypointense rim. Therefore, it seems 
likely that the SWI rim indicates a transitory BBB disturbance, 
rather than fulminant infection of oligodendrocytes, as seen in 
inﬂammatory PML.

The fact that, in 2 patients (patients 8 and 12 in the On-line 
Table), the presence of the peripheral rim of restricted diffusion 
was only present initially (as long as the SWI rim was not de-
tected) and disappeared later with the formation of the SWI rim 
further conﬁrms the hypothesis that the SWI rim represents the 
end-stage of neuroinflammation. Further prospective studies 
with a clearly deﬁned time period for the follow-up MR imaging 
examination may deliver data that will indicate the time range 
needed for an SWI rim to develop in long-term survivors.

One limitation of our study is the relatively small number of 
patients, which does not allow an estimation of the real incidence 
of an SWI dark rim in patients with PML. Ideally, prospective data 
should be collected from several institutions. Another limitation 
is the rather limited histopathologic data of only 2 patients. How-
ever, the patient with a dark SWI rim died soon after the PML 
diagnosis from a non-PML-related disease; thus, the changes ob-
served on histology most probably reﬂect ﬁndings in long-term 
survivors.

CONCLUSIONS

The formation of a thin, uniformly linear, gyriform SWI-hypo-
tense rim in the region of the paraseptal U-fibers in patients with 
PML seems to represent an end-point stage of the neuroinflam-
matory process in long-term survivors. Its morphologic correlate 
could be related to the chronic glio-inﬂammatory reaction, with
increased iron content in microglia, oligodendroglia, and astroglia, and is attributable to BBB leakage along the perivascular spaces.

**ACKNOWLEDGMENTS**

We are grateful to Mrs Irene Ebner of the Institute of Neurology of the Medical University of Vienna for the excellent technical neuropathologic work-up.


**REFERENCES**


